^
    4d
    Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system. (PubMed, J Immunother Cancer)
    This study identifies a mechanism of OH2-induced PD-L1 expression in PCa and provides a versatile, targeted delivery platform that enables effective intravenous viro-immunotherapy, overcoming key translational barriers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    BS001
    4d
    OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BS001 • BS006
    6ms
    OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (clinicaltrials.gov)
    P2, N=4, Terminated, Binhui Biopharmaceutical Co., Ltd. | N=45 --> 4 | Trial completion date: Dec 2025 --> Oct 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Oct 2024; Strategy adjustment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BS001
    7ms
    OH2 Injection in Melanoma (clinicaltrials.gov)
    P3, N=340, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • BS001
    7ms
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    7ms
    OH2 Oncolytic Viral Therapy in Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BS001
    7ms
    OH2 Injection in Combination With HX008 for Melanoma. (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Puyouheng (pucotenlimab) • BS001
    1year
    Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial. (PubMed, J Immunother Cancer)
    Intratumoral injection of oncolytic virus OH2 is well tolerable in patients with sarcoma. Further investigation of OH2 with HX008 in select sarcoma subtypes is warranted.
    P1/2 data • Journal
    |
    CSF2 (Colony stimulating factor 2)
    |
    Puyouheng (pucotenlimab) • BS001
    1year
    OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001
    1year
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • BS001
    1year
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001
    1year
    OH2 Administered by Intratumoral Injection (clinicaltrials.gov)
    P1, N=29, Not yet recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jul 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001